Mandate

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

January 24, 2025 Banking and Finance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.

The bonds carry a floating interest rate of STIBOR 3M + 4.00% and have a tenor of three years. EQL intends to apply for admission to trading of the bonds on Nasdaq Transfer Market and the corporate bond list of Nasdaq Stockholm. The net proceeds from the issuance will be used to finance the acquisition of a portfolio with original pharmaceuticals, repayment of existing financial indebtedness and for general corporate purposes.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, August Ahlin and Sara Jansson.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025